Fulcrum Therapeutics Inc (NAS:FULC)
$ 7.47 -0.03 (-0.4%) Market Cap: 464.29 Mil Enterprise Value: 238.89 Mil PE Ratio: 0 PB Ratio: 1.97 GF Score: 48/100

Q2 2020 Fulcrum Therapeutics Inc Earnings Call Transcript

Aug 11, 2020 / 12:00PM GMT
Release Date Price: $8.9 (-48.01%)
Operator

Good morning and welcome to the Fulcrum Therapeutics Conference Call. (Operator Instructions)

I'd now like to turn the call over to Christi Waarich, Director of Investor Relations and Corporate Communications at Fulcrum. Please proceed.

Christi Waarich
Fulcrum Therapeutics, Inc. - Director, Corporate Communications & IR

Thank you, Anthony. Good morning, and thank you for joining us. Earlier today, we issued 2 press releases: one, outlining the results of our interim analysis for losmapimod in FSHD; and another outlining our recent corporate progress and financial results for the second quarter of 2020. You can find both of these in the Investor Relations section of our website at fulcrumtx.com.

Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, clinical development time lines and financial projections. While these forward-looking statements represent

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot